NIFTP was formerly termed non-invasive encapsulated follicular variant of PTC (EFVPTC); its reclassification initiated by the Endocrine Pathology Society working group through an international multi-institutional study that established preponderance of RAS genetic aberrations (similar to follicular-derived lesions), deficient common PTC BRAFV600E genetic aberrations and indolent nature of EFVPTC, preventing overdiagnosis and overtreatment of these tumours [10]. This evidence concerns the gene RET and neoplasm.